Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

Blood

Volumn 107, Issue 8, 2006, Pages 3339-3341

  Jones, Amy V ^b   Silver, Richard T ^b   Waghorn, Katherine ^b   Curtis, Claire ^b   Kreil, Sebastian ^b   Zoi, Katerina ^b   Hochhaus, Andreas ^b   Oscier, David ^b   Metzgeroth, Georgia ^b   Lengfelder, Eva ^b   Reiter, Andreas ^b   Chase, Andrew J ^b   Cross, Nicholas C P ^a  

^a SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; JANUS KINASE 2; MUTANT PROTEIN; RECOMBINANT ALPHA INTERFERON;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG EFFECT; FEMALE; GENE FREQUENCY; HEMATOLOGICAL PARAMETERS; HUMAN; MALE; MOLECULAR DYNAMICS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REMISSION; SAMPLING; TREATMENT RESPONSE;

EID: 33645740979     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3917     Document Type: Article

References (22)

1. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol. 1994;86:233-235.
2. Silver RT. Interferon-a2b: a new treatment for polycythemia vera. Ann Int Med. 1993;119:1091-1092.
3. Messora C, Bensi L, Vecchi A, et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol. 1994;86:402-404.
4. Taylor PC, Dolan G, Ng JP, Paul B, Collin R, Reilly JT. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. Br J Haematol. 1996;92:55-59.
5. Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin Hematol. 1997;34:40-50.
6. Foa P, Massaro P, Caldiera S, et al. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. Eur J Haematol. 1998;60:273-277.
7. Lengfelder E, Berger U, Hehlmann R. Interferon alpha in the treatment of polycythemia vera. Ann Hematol. 2000;79:103-109.
8. Silver RT. Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera. Leukemia. 2003;17:1186-1187.
9. Jones CM, Dickinson TM. Polycythemia vera responds to imatinib mesylate. Am J Med Sci. 2003;325:149-152.
10. Silver RT. Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. Curr Hematol Rep. 2005;4:235-237.
11. Silver RT, Fruchtman SM, Feldman EJ, et al. Imatinib mesylate (Gleevec®) is effective in the treatment of polycythemia vera: a multi-institutional clinical trial [abstract]. Blood 2004;104(suppl 1):189a.
12. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
13. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
14. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
15. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
16. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788-22792.
17. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
18. Goerttler PS, Steimle C, Marz E, et al. The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood. 2005;106:2862-2864.
19. Wu H, Klingmuller U, Acurio A, Hsiao JG, Lodish HF. Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. Proc Natl Acad Sci U S A. 1997;94:1806-1810
20. Munugalavadla V, Kapur R. Role of c-Kit and erythropoietin receptor in erythropoiesis. Crit Rev Oncol Hematol. 2005;54:63-75.
21. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission: German CML Study Group and the UK MRC CML Study Group. Blood. 2000;95:62-66.
22. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.